Obesity
Eli Lilly’s Zepbound Becomes First and Only FDA Approved Weight Loss Drug to Treat Obstructive Sleep Apnea
2024-12-23
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (Second Part)
2024-03-07
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (First Part)
2024-02-15
Novo Nordisk Acquire Catalent for $16.5 Billion, Enhancing Obesity Drugs Production Capacity
2024-02-07
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19